levodopa has been researched along with Neurodegenerative Diseases in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (4.84) | 18.2507 |
| 2000's | 18 (29.03) | 29.6817 |
| 2010's | 17 (27.42) | 24.3611 |
| 2020's | 24 (38.71) | 2.80 |
| Authors | Studies |
|---|---|
| Dagda, R; Dagda, RK; Grigoruta, M; Martinez, B; Vazquez-Mayorga, E | 1 |
| Iguchi, Y; Murakami, H; Omoto, S; Shiraishi, T; Umehara, T | 1 |
| Cubo, E; Miranda, J | 1 |
| Alobaidi, A; Bao, Y; Chaudhuri, KR; Jalundhwala, YJ; Jones, G; Kandukuri, PL; Madin-Warburton, M; Najle-Rahim, S; Oddsdottir, J; Pickard, AS; Ridley, C; Schrag, A; Sus, J; Xu, W | 1 |
| Daida, K; Hattori, N; Kamo, R; Nishioka, K; Shimada, T; Tsunemi, T | 1 |
| Adachi, T; Hanajima, R; Hasegawa, M; Sakata, R; Sakuwa, M; Suzuki, Y; Takigawa, H | 1 |
| Lezzi, P; Lezzi, T; Lupo, R; Vitale, E | 1 |
| Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á | 1 |
| Fung, VS; Griffith, J; Qiu, J; Tsui, D; Waller, S; Williams, L | 1 |
| Liu, X; Ming, D; Moussian, B; Pang, M; Peng, R; Su, Y; Wang, P; Wang, Y; Zhu, Y | 1 |
| Fung, VSC; Griffith, J; Qiu, J; Tsui, D; Waller, S; Williams, L | 1 |
| Blandini, F; Cerri, S; Cesaroni, V | 1 |
| Chen, Y; Liu, JS; Pu, JL; Shi, DD; Zhang, BR | 1 |
| Kaminska, M; Lafontaine, AL; Scanga, A | 1 |
| Liu, X; Yang, G; Zhao, Y | 1 |
| Abdel-Aleem, GA; Abdel-Fattah, DS; El-Sheikh, TF; Elbatch, MM; Mohamed, AS | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE; Elewa, YHA; Papadakis, M; Zahran, MH | 1 |
| Abuzenadah, AM; Alghamdi, BS; Ashraf, GM; Chattopadhyay, S; Gautam, A; Jha, NK; Jonnalagadda, S; Kumar, L; Malik, S; Preetam, S; Rath, R | 1 |
| Baschieri, F; Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Provini, F; Sambati, L; Tonon, C; Vitiello, M | 1 |
| Hatano, T; Hattori, N; Kanai, K; Oyama, G; Shimo, Y; Ueno, SI | 1 |
| Deputy, SR; Tilton, AH | 1 |
| Blinova, NM; Derevyanko, HP; Safin, SM | 1 |
| Bril, EV; Fedorova, NV; Kulua, TK; Mikhaylova, AD | 1 |
| Goel, A; Narayan, SK; Sugumaran, R | 1 |
| Caldwell, GA; Caldwell, KA; Daniels, MJ; Doshi, S; Gould, NS; Grossman, JL; Gupta, P; Ischiropoulos, H; Kalb, RG; Kim, H; Mazzulli, JR; Mor, DE; Tan, VX; Tsika, E; Wolfe, JH | 1 |
| Ali, F; Josephs, KA | 1 |
| Cacciatore, I; Di Marco, V; Di Stefano, A; Ferrone, A; Franceschelli, S; Gabriele, M; Gatta, DMP; Marinelli, L; Orlando, G; Patruno, A; Speranza, L | 1 |
| Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T | 1 |
| Baul, HS; Manikandan, C; Sen, D | 1 |
| Morris, GP; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Arabia, G; Cerasa, A; Gioia, CM; Morelli, M; Novellino, F; Pugliese, P; Quattrone, A; Salsone, M | 1 |
| Ludwichowska, A; Szabat, K; Szadejko, K; Sławek, J | 1 |
| Cenci, MA | 1 |
| Goldstein, DS; Holmes, C; Kopin, IJ; Mash, DC; Sharabi, Y; Sidransky, E; Stefani, A; Sullivan, P | 1 |
| Canela, EI; Casadó, V; Cortés, A; Moreno, E; Rodríguez-Ruiz, M | 1 |
| Jog, M; Kumar, N | 1 |
| Ben, J; de Oliveira, PA; Matheus, FC; Moreira, ELG; Prediger, RD; Rial, D; Schwarzbold, ML; Walz, R | 1 |
| Ugrumov, MV | 1 |
| Aguilar, E; Barbanoj, M; Kulisevsky, J; Marin, C; Pérez, V; Rubio, A | 1 |
| Schneemilch, C | 1 |
| Espay, AJ; Metman, LV; O'Sullivan, JD; Paviour, DC; Revilla, FJ; Schmidt, RE | 1 |
| Björklund, A; Decressac, M; Lundblad, M; Mattsson, B; Weikop, P | 1 |
| Borah, A; Mohanakumar, KP | 1 |
| Brus, R; Kostrzewa, JP; Kostrzewa, RM | 1 |
| Iseki, E | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
| Farsang, M; Kovács, T; Szirmai, I; Takáts, A | 1 |
| Funakawa, I; Katayama, S; Konishi, Y; Shirabe, T; Terao, A | 1 |
| Bottiglieri, T; Diaz-Arrastia, R; Greenberg, SM; Growdon, JH; Gurol, ME; Hyman, BT; Irizarry, MC; Locascio, JJ; Raju, S; Tennis, M | 1 |
| Brundin, P; Popovic, N | 1 |
| Ikoma, Y; Ito, H; Maeda, J; Nakao, R; Ota, M; Seki, C; Suhara, T; Suzuki, K; Takano, A; Yasuno, F | 1 |
| Clement, F; Coubes, P; Defebvre, L; Destee, A; Devos, D; Moreau, C | 1 |
| Kagamihara, Y | 1 |
| Katayama, S; Khoriyama, T; Mao, JJ; Nakamura, S; Oka, M; Tahara, E; Watanabe, C; Yamamura, Y | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; Martín, AB; O'Shea, E | 1 |
| Gwinn-Hardy, K; Hardy, J | 1 |
| Chin, S; Dhawan, V; Eidelberg, D; Fahn, S; Frucht, S | 1 |
| Kidd, PM | 1 |
| Mueller, J; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Wenning, GK | 1 |
| Jankovic, J; Vanek, Z | 1 |
| Peschanski, M | 1 |
23 review(s) available for levodopa and Neurodegenerative Diseases
| Article | Year |
|---|---|
Recent Advances in Drug Therapy for Parkinson's Disease.
Topics: Antiparkinson Agents; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2023 |
The Prephase Nursing in Levodopa Carbidopa Intestinal Gel Therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease.
Topics: Aged; Biological Products; Carbidopa; Cholinergic Antagonists; Dopamine; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life | 2022 |
Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
Topics: Antiparkinson Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Pharmacogenetics; Prospective Studies | 2023 |
An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson's disease.
Topics: Dopamine Agonists; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life; Sleep Wake Disorders | 2023 |
Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.
Topics: Brain; Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Receptors, Purinergic P1 | 2023 |
Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
Topics: Dopaminergic Neurons; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Substantia Nigra | 2023 |
Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease.
Topics: Dopamine; Humans; Levodopa; Lipids; Neurodegenerative Diseases; Parkinson Disease | 2023 |
Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.
Topics: Autoimmune Diseases; Cerebral Palsy; Child; Dyskinesias; Humans; Levodopa; Metabolism, Inborn Errors; Movement Disorders; Muscle Tonus; Neurodegenerative Diseases; Physical Therapy Modalities; Treatment Outcome | 2020 |
[Progressive supranuclear palsy].
Topics: Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Neuroimaging; Parkinson Disease; Supranuclear Palsy, Progressive | 2021 |
Zonisamide in Parkinson's disease: a current update.
Topics: Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Zonisamide | 2021 |
Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.
Topics: Cannabinoids; Dopaminergic Neurons; Endocannabinoids; Humans; Levodopa; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Receptors, Cannabinoid | 2019 |
[Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Topics: Catechol O-Methyltransferase Inhibitors; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Vitamin B Complex | 2013 |
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.
Topics: Animals; Dyskinesias; Dystonia; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2014 |
Targeting the dopamine D3 receptor: an overview of drug design strategies.
Topics: Animals; Dopamine; Dopamine Agonists; Dopamine Antagonists; Drug Design; Drug Partial Agonism; Humans; Levodopa; Ligands; Molecular Targeted Therapy; Neurodegenerative Diseases; Receptors, Dopamine D3 | 2016 |
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamus; Levodopa; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase | 2009 |
Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Dopamine; Humans; Levodopa; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species | 2002 |
[Corticobasal degeneration].
Topics: Aged; Basal Ganglia; Cerebral Cortex; Cholinergic Antagonists; Diagnosis, Differential; Diagnostic Imaging; Dopamine Agonists; Female; Humans; Levodopa; Neurodegenerative Diseases | 2003 |
[Clinical features of corticobasal degeneration].
Topics: Aged; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Diagnosis, Differential; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Degeneration; Neurodegenerative Diseases; Parkinson Disease | 2005 |
Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Brain; Delayed-Action Preparations; Diffusion; Disease Models, Animal; Drug Carriers; Drug Stability; Humans; Huntington Disease; Levodopa; Microspheres; Nerve Growth Factor; Neurodegenerative Diseases; Neuroprotective Agents; Parkinsonian Disorders; Polymers; Solubility | 2006 |
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Topics: Disease Progression; Electron Transport; Humans; Levodopa; Mitochondria; Neurodegenerative Diseases; Oxidation-Reduction; Parkinson Disease, Secondary; Parkinsonian Disorders | 2000 |
[Parkinson's disease: diagnostic and therapeutic criteria. Short text].
Topics: Antiparkinson Agents; Combined Modality Therapy; Diagnosis, Differential; Dopamine Agonists; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Neurosurgical Procedures; Parkinson Disease; Patient Education as Topic; Physical Therapy Modalities; Severity of Illness Index; Stereotaxic Techniques | 2000 |
39 other study(ies) available for levodopa and Neurodegenerative Diseases
| Article | Year |
|---|---|
Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.
Topics: Animals; Colforsin; Disease Models, Animal; Dopaminergic Neurons; Humans; Levodopa; Mesencephalon; Neurodegenerative Diseases; Parkinson Disease; Protein Kinases; Rats; Substantia Nigra | 2022 |
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders | 2022 |
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia.
Topics: Brain; Calcinosis; Cerebellar Ataxia; Corpus Striatum; Female; Humans; Levodopa; Neurodegenerative Diseases; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon | 2022 |
An autopsy case of progressive supranuclear palsy. Pallido-nigro-luysian type with argyrophilic grains clinically presenting with personality and behavioral changes.
Topics: Aged; Aged, 80 and over; Atrophy; Autopsy; Humans; Levodopa; Male; Neurodegenerative Diseases; Personality; Supranuclear Palsy, Progressive; tau Proteins | 2022 |
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies | 2022 |
An approach to acute clinical deterioration in patients with late-stage Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Deterioration; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Challenges in managing late-stage Parkinson's disease: Practical approaches and pitfalls.
Topics: Humans; Levodopa; Neurodegenerative Diseases; Pain; Parkinson Disease; Psychotic Disorders | 2022 |
Biochemical study of the effect of mesenchymal stem cells-derived exosome versus L-Dopa in experimentally induced Parkinson's disease in rats.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Exosomes; Humans; Levodopa; Male; Mesenchymal Stem Cells; MicroRNAs; Neurodegenerative Diseases; Parkinson Disease; Rats; RNA, Circular; Ubiquitin-Protein Ligases | 2023 |
The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population.
Topics: Aged; Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Prospective Studies | 2020 |
A Retrospective Imaging Evaluation of Presynaptic Dopaminergic Degeneration in Multiple System Atrophy with Levodopa Induced Dyskinesia.
Topics: Aged; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neostriatum; Neurodegenerative Diseases; Presynaptic Terminals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes | 2020 |
[Progressive supranuclear paralysis with levodopa-induced dyskinesia].
Topics: Aged; Dyskinesias; Humans; Levodopa; Movement Disorders; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | 2021 |
Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Cells, Cultured; Corpus Striatum; Dopamine; Dopaminergic Neurons; Female; Humans; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurodegenerative Diseases; Substantia Nigra | 2017 |
Corticobasal degeneration: key emerging issues.
Topics: Aniline Compounds; Basal Ganglia; Carbolines; Cerebral Cortex; Dopamine Agents; History, 20th Century; Humans; Levodopa; Neurodegenerative Diseases; Positron-Emission Tomography; Supranuclear Palsy, Progressive; Thiazoles | 2018 |
Chelating and antioxidant properties of l-Dopa containing tetrapeptide for the treatment of neurodegenerative diseases.
Topics: Animals; Antioxidants; Catalase; Cell Line; Cell Survival; Chelating Agents; Glutathione; Humans; Levodopa; Neurodegenerative Diseases; Oxidative Stress; Reactive Oxygen Species; Superoxide Dismutase | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger | 2018 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure | 2019 |
Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
Topics: Age of Onset; Aged; Antiparkinson Agents; Cerebral Cortex; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Levodopa; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neurodegenerative Diseases; Normal Distribution; Parkinson Disease; Substantia Nigra | 2013 |
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.
Topics: Autopsy; Catecholamines; Fluorodeoxyglucose F18; Humans; Levodopa; Neurodegenerative Diseases; Neurons; Parkinson Disease; Putamen; Synaptic Vesicles | 2015 |
Fahr's Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Calcinosis; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Neurodegenerative Diseases | 2017 |
Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Brain Injuries; Brain Injuries, Traumatic; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Levodopa; Mice; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidopamine; Tyrosine 3-Monooxygenase | 2017 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Maze Learning; Medial Forebrain Bundle; Memory, Short-Term; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Time Factors | 2009 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.
Topics: Adolescent; Brain; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Magnetic Resonance Imaging; Neurodegenerative Diseases; Parkinsonian Disorders; Young Adult | 2010 |
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Symptoms; Cell Count; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; ELAV Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Humans; Levodopa; Mesencephalon; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regulatory Elements, Transcriptional; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2012 |
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders | 2012 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
Autopsy case of pure akinesia showing pallidonigro-luysian atrophy.
Topics: Atrophy; Brain; Dopamine Agonists; Drug Resistance; Gait Apraxia; Humans; Immunohistochemistry; Levodopa; Male; Middle Aged; Neurodegenerative Diseases; Plaque, Amyloid | 2005 |
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amyloid beta-Peptides; Brain; Causality; Cerebral Amyloid Angiopathy; Cognition Disorders; Creatinine; Female; Folic Acid; Homocysteine; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Predictive Value of Tests; Vitamin B 12 | 2005 |
Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[beta-11C]DOPA.
Topics: Adult; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Humans; Kinetics; Levodopa; Male; Neurodegenerative Diseases; Positron-Emission Tomography; Time Factors | 2006 |
Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic options.
Topics: Adolescent; Brain; Brain Diseases, Metabolic; Diagnosis, Differential; DNA Mutational Analysis; Dystonia; Female; Genetic Predisposition to Disease; Humans; Iron; Iron Metabolism Disorders; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neurodegenerative Diseases; Pantothenate Kinase-Associated Neurodegeneration; Phosphotransferases (Alcohol Group Acceptor); Treatment Outcome | 2007 |
[Atypical corticobasal degeneration with clinical pictures of Parkinson's disease--an L-dopa-effective case].
Topics: Aged; Basal Ganglia; Cerebral Cortex; Diagnosis, Differential; Dopamine Agents; Female; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease | 2007 |
Slowly progressive L-DOPA nonresponsive pure akinesia due to nigropallidal degeneration: a clinicopathological case study.
Topics: Disease Progression; Dopamine Agents; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurodegenerative Diseases; Substantia Nigra; Treatment Failure | 1998 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Serotonin | 1999 |
Neurodegenerative disease: a different view of diagnosis.
Topics: Alzheimer Disease; Dementia; Dopamine Agents; Humans; Levodopa; Lewy Bodies; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Prion Diseases; Synucleins; tau Proteins | 1999 |
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Basal Ganglia Diseases; Cerebral Cortex; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurodegenerative Diseases; Neurologic Examination; Parkinson Disease | 2000 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Epilepsy, Tonic-Clonic; Humans; Inclusion Bodies; Levodopa; Mice; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-1; Shy-Drager Syndrome; Syndrome; Synucleins; Tyrosine 3-Monooxygenase | 2001 |
Dystonia in corticobasal degeneration.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Basal Ganglia; Botulinum Toxins; Cerebral Cortex; Contracture; Dopamine Agonists; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Neurodegenerative Diseases; Pain; Retrospective Studies | 2001 |
[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].
Topics: Animals; Brain Tissue Transplantation; Cells, Cultured; Combined Modality Therapy; Cricetinae; Fetal Tissue Transplantation; Forecasting; France; Humans; Huntington Disease; Levodopa; Neurodegenerative Diseases; Neurons; Parkinson Disease; Rabbits; Rats; Species Specificity; Stem Cell Transplantation; Swine; Tissue and Organ Procurement; Transplantation, Heterologous; Transplantation, Homologous; Treatment Outcome | 2001 |